Assay Development for Superior Understanding of Response and Efficacy (ASSURE)
ID: RRPV-26-07-ASSUREType: Solicitation
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFOFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSEASPR BARDA DIV CONTRACTS MGMT & ACQWashington, DC, 20515, USA

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

PSC

HEALTH R&D SERVICES; HEALTH CARE - OTHER; APPLIED RESEARCH (AN42)

Set Aside

No Set aside used (NONE)

Original Source

https://sam.gov/workspace/contract/opp/774b1c03c1b544e0b086a28eede6b5c8/view
Timeline
    Description

    The Department of Health and Human Services, through the Office of Assistant Secretary for Preparedness and Response (ASPR BARDA), is soliciting proposals for the ASSURE program, which focuses on the development of innovative assays to evaluate immune responses to infections and vaccinations. The primary objective is to create multiplexed, high-throughput, scalable, and sample-sparing assays that can assess immune status in response to chemical, biological, radiological, and nuclear (CBRN) threats, pandemic influenza, and other emerging infectious diseases. Approximately $8 million is available for four to five awards, with proposals evaluated based on technical approach, relevant experience, and cost reasonableness. Interested parties must submit an abstract by December 18, 2025, and can contact Rebecca Harmon at rebecca.harmon@ati.org or 843.760.3358 for further information.

    Point(s) of Contact
    Rebecca Harmon
    (843) 760-3358
    rebecca.harmon@ati.org
    Files
    Title
    Posted
    RPPV 26-07-ASSURE.docx
    The Biomedical Advanced Research and Development Authority (BARDA) is seeking proposals for its Rapid Response Partnership Vehicle (RRPV) program, RRPV 26-07-ASSURE. This Request for Project Proposals (RPP), issued on November 14, 2025, with a due date of December 18, 2025, aims to develop innovative, multiplexed, high-throughput, scalable, and sample-sparing assays. These assays will comprehensively evaluate an individual’s immune status in response to infection or vaccination, particularly focusing on cell-mediated and mucosal immunity. The program seeks to de-risk novel assay platform technologies to assess immune responses to CBRN threats, pandemic influenza, or other emerging infectious diseases. Approximately $8 million is available for four to five awards. The solicitation follows a two-stage approach: an initial abstract submission, followed by an invitation-only full technical and cost proposal. Mandatory eligibility requires offerors to be RRPV members upon abstract submission. Proposals will be evaluated based on technical approach, relevant experience, and cost reasonableness.
    Lifecycle
    Title
    Type
    Assay Development for Superior Understanding of Response and Efficacy (ASSURE)
    Currently viewing
    Solicitation
    Similar Opportunities
    Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)
    Buyer not available
    The Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority (BARDA), is soliciting proposals under the Broad Agency Announcement (BAA) BAA-23-100-SOL-00004 for advanced research and development of Medical Countermeasures (MCMs) targeting chemical, biological, radiological, nuclear threats, and emerging infectious diseases, including pandemic influenza. The initiative aims to enhance public health preparedness by fostering partnerships with private organizations, government laboratories, and academic institutions to expedite the development of life-saving MCMs critical for national health security. Proposals will be evaluated based on scientific merit, technological maturity, and regulatory compliance, with an open submission period running until September 25, 2028, at 4:30 PM Eastern Time. Interested parties should direct inquiries to BARDA-BAA@hhs.gov for further information.
    BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response
    Buyer not available
    The Department of Health and Human Services, specifically the Office of Assistant Secretary for Preparedness and Response (BARDA), is seeking qualified contractors to support the development of vaccine medical countermeasures for pandemic influenza preparedness and response. The objective of this Sources Sought Notice (SSN) is to refine requirements and establish long-term partnerships with contractors capable of producing vaccines, antigens, and adjuvants necessary for pandemic preparedness and public health emergencies. This initiative is critical for enhancing the U.S. response to influenza viruses with pandemic potential and ensuring rapid regulatory decisions and manufacturing readiness. Interested parties must submit evidence of eligibility, capabilities statements, and requests to participate by email to Laura Saddison at Laura.Saddison@hhs.gov by 3:00 pm EST on December 19, 2025. This SSN/RFI is for information and planning purposes only and does not constitute a solicitation.
    BARDA DRIVe EZ-BAA (EZBAA - 22-100-SOL-00003)
    Buyer not available
    The Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority (BARDA), is soliciting proposals under the Easy Broad Agency Announcement (EZ-BAA) BAA-22-100-SOL-00003, which focuses on innovative research to enhance public health preparedness against various biomedical threats. The initiative encompasses multiple Areas of Interest (AOIs), including the development of medical countermeasures for emerging infectious diseases, repurposing existing drugs for chemical threats, and advancing technologies for at-home diagnostics. Interested parties must have active registration with SAM.gov and are encouraged to engage in pre-submission consultations; abstract submissions are due by specified deadlines, with funding amounts contingent on the quality of proposals and alignment with program goals. For further inquiries, interested vendors can contact the BARDA DCMA DRIVe Team at DRIVeAcquisitions@hhs.gov.
    COVID 19 Tests
    Buyer not available
    The Department of Health and Human Services, specifically the Office of Assistant Secretary for Preparedness and Response, is seeking procurement for COVID-19 tests. The opportunity involves the acquisition of in vitro diagnostic substances, reagents, test kits, and sets, with a focus on ensuring compliance with the Trade Agreements Act (TAA). This procurement is critical for enhancing the nation's testing capabilities in response to the ongoing pandemic. Interested vendors can reach out to Junli Collins at junli.collins@hhs.gov or Judy Williams at judy.williams2@hhs.gov for further details, as outlined in the attached justification document.
    Resilient Systems Office (RSO) Mission Office Innovative Solutions Opening (ISO)
    Buyer not available
    The Department of Health and Human Services, through the Advanced Research Projects Agency for Health (ARPA-H), is soliciting proposals for the Resilient Systems Office (RSO) Mission Office Innovative Solutions Opening (ISO). This opportunity invites submissions that address systemic challenges in healthcare and public health by leveraging innovative technologies to improve care quality, efficacy, and accessibility. Proposals will be evaluated based on scientific merit, alignment with ARPA-H's mission, proposer capabilities, and cost, with a focus on open-source intellectual property and compliance with research regulations. Interested parties must submit solution summaries and proposals via the designated ARPA-H portal, with the closing date for submissions set for March 5, 2029. For further inquiries, proposers can reach out through the same portal.
    Domestic Capability Building Activity – Onshoring the Manufacturing of Viral Hemorrhagic Fever Vaccine Candidates
    Buyer not available
    The Department of Health and Human Services, specifically the Office of Assistant Secretary for Preparedness and Response (BARDA), is seeking to enhance domestic biopharmaceutical manufacturing capabilities through a contract focused on onshoring the production of viral hemorrhagic fever vaccine candidates. The primary objective is to transfer the manufacturing processes for Vesicular Stomatitis Virus (VSV) Delta G based vaccine candidates from international sites to domestic Contract Development and Manufacturing Organizations (CDMOs) in the United States, thereby strengthening national health security preparedness against threats like the Marburg and Sudan viruses. This initiative is critical as it addresses the current limited domestic capacity for live viral vector manufacturing, ensuring a robust response to infectious disease challenges. Interested parties must be product sponsors or technology owners with BARDA-sponsored monovalent filovirus vaccine candidates and should prepare for a technology transfer demonstration, as the scope does not include procurement of investigational or licensed products.
    BioStabilization Systems (BoSS)
    Buyer not available
    The Department of Health and Human Services, through the Advanced Research Projects Agency for Health (ARPA-H), is seeking proposals for the BioStabilization Systems (BoSS) program aimed at revolutionizing the stabilization, manufacturing, and distribution of live cell-based therapies. The program addresses the critical challenge of ultra-cold storage requirements for advanced cell and gene therapies by developing bioprocessing systems that enable the production of thermally stable cells, thereby enhancing the efficiency and resilience of biologics distribution. Interested parties can submit Solution Summaries for consideration as either Performer teams or Independent Verification and Validation (IV&V) partners, with deadlines set for February 19, 2026, and April 17, 2026, respectively. For more information, including submission guidelines and program details, please visit the ARPA-H website or refer to the attached documents.
    Scalable Solutions Office (SSO) Mission Office Innovative Solutions Opening (ISO)
    Buyer not available
    The Department of Health and Human Services, through the Advanced Research Projects Agency for Health (ARPA-H), is soliciting proposals for the Innovative Solutions Opening (ISO) under the Scalable Solutions Office (SSO). This initiative aims to develop innovative solutions that enhance healthcare access, affordability, and distribution, particularly in underserved communities, while addressing challenges in biomanufacturing and health technology distribution. The solicitation is open until March 5, 2029, and encourages submissions from academia, non-profits, and for-profit entities, with multiple awards anticipated as Other Transactions. Interested parties must submit a Solution Summary for initial feedback before proceeding with a full proposal, adhering to strict guidelines on intellectual property, research security, and cost proposal requirements. For further details, proposers can reach out through the designated submission portals and must ensure compliance with the updated administrative and national policy requirements outlined in the solicitation documents.
    Health Science Futures (HSF) Mission Office Innovative Solutions Opening (ISO)
    Buyer not available
    The Department of Health and Human Services, through the Advanced Research Projects Agency for Health (ARPA-H), is soliciting proposals for the Health Science Futures (HSF) Mission Office Innovative Solutions Opening (ISO). This initiative aims to gather innovative solutions that address future healthcare challenges, focusing on groundbreaking research in areas such as maternal/fetal medicine, genetic therapies, chronic diseases, and mental health, while excluding proposals for incremental advances or clinical trials. Proposers are required to submit a Solution Summary for initial feedback, followed by a detailed proposal that adheres to updated administrative and national policy requirements, including compliance with ethical research guidelines and research security disclosures. Interested parties should submit their proposals via the designated ARPA-H portal, with specific deadlines and further details available through the provided links.
    BROAD AGENCY ANNOUNCEMENT (BAA) RESEARCH AND DEVELOPMENT IN SUPPORT OF THE JOINT PROGRAM EXECUTIVE OFFICE FOR CHEMICAL, BIOLOGICAL, RADIOLOGICAL AND NUCLEAR DEFENSE (JPEO-CBRND), JPM MEDICAL AND JPL EB
    Buyer not available
    Solicitation DEPT OF DEFENSE is seeking research and development services in support of the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), JPM Medical and JPL EB. The service being procured is for the identification of the best available science in the areas of research interest, including novel solutions and improved methods for developing medical countermeasures. The government is specifically interested in enabling technologies, life cycle bioinformatics, and improved logistics tracking. The procurement notice is available on SAM.gov and the JPEO-CBD website. Potential offerors are encouraged to communicate with the JPMO technical contacts for proposal ideas. For any questions or inquiries, contact usarmy.detrick.mcs.mbx.baa@mail.mil.